<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02080767</url>
  </required_header>
  <id_info>
    <org_study_id>M-10331</org_study_id>
    <secondary_id>S-11-10</secondary_id>
    <nct_id>NCT02080767</nct_id>
  </id_info>
  <brief_title>Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure</brief_title>
  <official_title>Clinical Protocol to Treat Individuals With Tecovirimat (ST-246) After Exposure to Orthopox Viruses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical protocol is to treat individuals with Tecovirimat after exposure&#xD;
      to orthopox viruses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Smallpox</condition>
  <condition>Monkeypox</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tecovirimat</intervention_name>
    <description>Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)</description>
    <other_name>ST 246</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DoD-affiliated personnel (including US civilian employees, contractors and other US&#xD;
             personnel and dependents, as well as allied military forces and local nationals) of&#xD;
             any age, not breastfeeding&#xD;
&#xD;
          -  Has been exposed to or infected with orthopox viruses (ie, variola (smallpox),&#xD;
             vaccinia, monkeypox, or cowpox) OR Has developed serious complications from vaccinia&#xD;
             vaccination (eg, eczema vaccinatum, progressive vaccinia, generalized vaccinia that is&#xD;
             severe or persistent, and select cases of inadvertent inoculation due to severe pain&#xD;
             related to mucosal involvement, ocular involvement) resulting from vaccination,&#xD;
             secondary transmission, or other exposure&#xD;
&#xD;
          -  Is available for clinical follow-up for duration of the treatment and follow-up period&#xD;
&#xD;
          -  Must be able to swallow capsules&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has hypersensitivity to tecovirimat&#xD;
&#xD;
          -  Unable or unwilling to cooperate with the requirements of the treatment protocol&#xD;
&#xD;
          -  Breast-feeding patients. Note that breast-feeding females will be counseled that&#xD;
             tecovirimat has not been studied in breast-feeding women and may opt to cease&#xD;
             breast-feeding for the duration of the treatment and at least 30 days after the last&#xD;
             dose of drug and thus be eligible for enrollment. Women who choose to continue&#xD;
             breast-feeding will not be enrolled in this treatment protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Frances K Devlin</last_name>
    <phone>301-619-9904</phone>
    <email>frances.k.devlin.ctr@mail.mil</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James W Karaszkiewicz, PhD</last_name>
    <phone>301-619-6809</phone>
    <email>James.W.Karaszkiewicz.ctr@mail.mil</email>
  </overall_contact_backup>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smallpox</mesh_term>
    <mesh_term>Monkeypox</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

